Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. is a biopharmaceutical company dedicated to discovering and developing innovative treatments for challenging diseases characterized by inflammation and fibrosis. It primarily focuses on therapeutic interventions targeting the interplay between inflammation and fibrotic tissues, which are implicated in a variety of serious health conditions. The company's research is rooted in understanding the molecular pathways that contribute to these diseases, leveraging advanced technologies to create targeted treatment options. Operating within the healthcare and biotechnology sectors, Chemomab Therapeutics addresses unmet medical needs in diseases such as liver fibrosis and systemic sclerosis, which have limited effective treatment options. With its commitment to groundbreaking research, Chemomab plays a significant role in the medical field, contributing to the evolving landscape of treatment possibilities for complex diseases. Headquartered in Israel, the company is strategically positioned in a region known for technological innovation, facilitating its mission to translate scientific discoveries into clinical applications that can improve patient outcomes worldwide.